The combination of HMA and FLT3 inhibitor in FLT3-mutated unfit AML patients has been evaluated in several phase 1/2 studies, and a randomized phase 3 trial testing the combination of azacitidine with the FLT3 inhibitor gilteritinib is currently ongoing (NCT02752035). Here, FLT3 is linked to acute myeloid leukemia.